Collet-Solberg P F, Sernyak H, Satin-Smith M, Katz L L, Sutton L, Molloy P, Moshang T
Department of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania, USA.
Clin Endocrinol (Oxf). 1997 Jul;47(1):79-85. doi: 10.1046/j.1365-2265.1997.2211032.x.
We have evaluated the frequency of endocrine abnormalities in a large group of patients with hypothalamic/chiasmatic glioma (H/CG) and its correlation with the different forms of therapy.
Descriptive retrospective study using case note review analysis.
The records of 68 children who survived H/CG were analysed. One third had neurofibromatosis. The mean age at tumour presentation was 5 years. The median time of follow-up was 3.6 years. Thirty-eight children received cranial radiation, of whom 17 also had surgery. Surgery was performed in a total of 24 patients. Fifteen patients received only chemotherapy. Eight children, all with neurofibromatosis, received no specific tumour treatment.
Endocrine dysfunction was determined by clinical manifestations and biochemical evaluation of hypothalamic-pituitary function.
Endocrine dysfunction occurred in 42% of the children. The most common disorder was GH deficiency (GHD). Of 50 children evaluated, 15 of the 19 with GHD received cranial irradiation (P < 0.05). HOwever, 15 children treated with more than 15 Gy grew normally. Precocious puberty was diagnosed in 11 patients. Nine patients, all treated with cranial irradiation, developed hypogonadotrophic hypogonadism. Of the 14 patients with hypothyroidism, 10 had surgery (P < 0.005). Hypoadrenalism and diabetes insipidus each occurred in eight patients, and were associated with multiple endocrine deficiencies and surgery. Endocrine deficiencies occurred in children with neurofibromatosis as frequently as children without neurofibromatosis but only when comparing those treated with cranial irradiation or surgery.
Nearly all studies assessing the patients with different tumour therapy evaluate patients wit different tumour types. This study investigates a specific and large population of patients with H/CG and correlates the different form of treatment with the endocrine outcome. Precocious puberty, in children with this tumour, is probably due to tumour location rather than oncological therapy. Conversely, although endocrine deficiencies can be a result of tumour location, the major causes of endocrine abnormalities were field irradiation and tumour surgery. A notable finding not previously reported is that endocrine dysfunction occurs less often in neurofibromatosis patients treated conservatively. Furthermore, this study documents that a significant number of young children grew normally despite receiving brain irradiation of greater than 45 Gy.
我们评估了一大组下丘脑/视交叉胶质瘤(H/CG)患者内分泌异常的发生率及其与不同治疗方式的相关性。
采用病例记录回顾分析的描述性回顾性研究。
分析了68例H/CG存活患儿的记录。三分之一患有神经纤维瘤病。肿瘤出现时的平均年龄为5岁。随访时间中位数为3.6年。38例患儿接受了颅脑放疗,其中17例还接受了手术。共有24例患者接受了手术。15例患者仅接受了化疗。8例患儿,均患有神经纤维瘤病,未接受特定的肿瘤治疗。
通过下丘脑-垂体功能的临床表现和生化评估确定内分泌功能障碍。
42%的患儿出现内分泌功能障碍。最常见的疾病是生长激素缺乏症(GHD)。在50例接受评估的患儿中,19例GHD患儿中有15例接受了颅脑照射(P<0.05)。然而,15例接受超过15 Gy照射的患儿生长正常。11例患者被诊断为性早熟。9例患者,均接受了颅脑照射,出现了低促性腺激素性性腺功能减退。在14例甲状腺功能减退患者中,10例接受了手术(P<0.005)。肾上腺皮质功能减退症和尿崩症各有8例患者发生,且与多种内分泌缺陷和手术有关。神经纤维瘤病患儿与无神经纤维瘤病患儿内分泌缺陷的发生率相同,但仅在比较接受颅脑照射或手术的患儿时如此。
几乎所有评估不同肿瘤治疗患者的研究都评估了不同肿瘤类型的患者。本研究调查了一大群特定的H/CG患者,并将不同的治疗方式与内分泌结果相关联。患有这种肿瘤的儿童性早熟可能是由于肿瘤位置而非肿瘤治疗。相反,虽然内分泌缺陷可能是肿瘤位置的结果,但内分泌异常的主要原因是局部照射和肿瘤手术。一个以前未报道的显著发现是,保守治疗的神经纤维瘤病患者内分泌功能障碍的发生率较低。此外,本研究记录了相当数量的幼儿尽管接受了大于45 Gy的脑部照射仍生长正常。